IN8bio Inc
INAB
Company Profile
Business description
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.
Contact
350 5th Avenue
Suite 5330
New YorkNY10118
USAT: +1 646 600-6438
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
17
Stocks News & Analysis
stocks
Oracle earnings: Solid execution secures revenue target and mitigates investor concerns
We raise our fair value estimate for Oracle stock.
stocks
US dividend shares are getting a boost from the HALO trade. Can it last?
Both high-dividend stocks and dividend-growth stocks are outperforming amid AI disruption.
stocks
Unconventional wisdom: A modern day bank run
Is the economy and investor portfolios at risk from a potential ‘bank run’ in private credit?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,839.10 | 26.30 | 0.30% |
| CAC 40 | 7,911.53 | 72.91 | -0.91% |
| DAX 40 | 23,447.29 | 142.36 | -0.60% |
| Dow JONES (US) | 46,558.47 | 119.38 | -0.26% |
| FTSE 100 | 10,261.15 | 44.00 | -0.43% |
| HKSE | 25,465.60 | 251.16 | -0.98% |
| NASDAQ | 22,105.36 | 206.62 | -0.93% |
| Nikkei 225 | 53,819.61 | 633.35 | -1.16% |
| NZX 50 Index | 13,187.34 | 11.95 | -0.09% |
| S&P 500 | 6,632.19 | 40.43 | -0.61% |
| S&P/ASX 200 | 8,617.10 | 29.20 | 0.34% |
| SSE Composite Index | 4,095.45 | 33.65 | -0.82% |